Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

David Bushinsky

Nephrology Rochester, NY Medical Doctor

NPI 1629012265 CMS profile 209031

601 Elmwood Ave, Box Med, Rochester, NY 14642

Open in the dashboard

General payments

$43,767

28 records reported · program years 2019–2022

Research payments

$17,737

Paid to them · 15 records reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, David Bushinsky of Rochester, NY is reported in the CMS Open Payments database as having received $43,767 across 28 general payments and $17,737 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $73 1
2021 General $249 1
2021 Research $1,275 6
2020 General $8,827 8
2020 Research $7,093 4
2019 General $34,617 18
2019 Research $9,369 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Bushinsky
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to David Bushinsky were reported at $0. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year David Bushinsky Nephrology median Middle half National median
2019 $34,617 $236 $90–$588 $163
2020 $8,827 $135 $46–$364 $114
2021 $249 $202 $67–$551 $132
2022 $73 $242 $77–$695 $149
2023 $0 $254 $84–$766 $160
2024 $0 $300 $99–$852 $164
2025 $0 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Sanofi-Aventis U.S. LLC $25,664 8 payments
  2. Relypsa, Inc. $9,954 11 payments
  3. Fresenius USA Marketing, Inc. $6,276 7 payments
  4. Vifor (International) Ltd. $1,800 1 payment
  5. Vertex Pharmaceuticals Incorporated $73 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Travel and Lodging $17,587 15 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,963 2 payments
  3. Consulting Fee $9,049 6 payments
  4. Food and Beverage $693 4 payments
  5. Gift $475 1 payment
Products named General payments · program years 2019–2022
  1. RENVELA Renal $24,086 4 payments
  2. Veltassa Hyperkalemia $9,954 11 payments
  3. Veltassa Potassium Binder $1,800 1 payment
  4. RENVELA Nephrology $1,578 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2022
  1. Amgen Inc. $12,637 4 payments
  2. Novo Nordisk AS $5,100 11 payments

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record